Re-Importation: A Looming Antitrust Concern for Biotechs?
Executive Summary
With federal legislation to allow drug reimportation mired in the US Senate following passage of a bill in the House of Representatives last year, US biotechs must wrestle with an immediate question: how to prevent their ex-US partners from becoming sources of low-cost imports of their products?You may also be interested in...
UK Price Increases Add To Pharmacy Burden
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
QUOTED. 13 December 2019. Todd Garner
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Need a specific report? 1000+ reports available
Buy Reports